#medical-imaging #biomarkers #ophthalmology #retina

imagine eyes®

Fighting blindness with advanced retinal imaging



Manufacturer of ophthalmic imaging devices, Imagine Eyes is the leading pioneer in high-resolution retinal imaging. With our products, clinicians examine the back of the eye like under a microscope. We provide new, superior biomarkers of retinal diseases, and we exploit them in collaboration with pharma sponsors and investigators.

rtx1™ Adaptive Optics Retinal Camera

3µm resolution

2s acquisition



Cellular biomarkers

Microvascular biomarkers

Key figures & references

Team: **20** experts in biophotonics and ophthalmic imaging

Latest funding: **€ 4.9m** from the European Commission

Technology proven by **250+** peer-reviewed publications

rtx1 adopted by **90+** clinical centers in **18** countries

New biomarkers for clinical trials

Imagine Eyes proposes to accelerate the clinical development of new retinal treatments, with the implementation of highly sensitive biomarkers.

Compared with state-of-the-art techniques, rtx1 biomarkers allow measuring the progression of retinal diseases on timescales that are 5 times shorter, and deliver much earlier signals of treatment safety and effectiveness.

Expected benefits

- **Five-fold acceleration** of clinical investigations in new retinal therapies
- **Multimillion dollar savings** in clinical development costs
- **New capabilities** to further personalize therapies for retinal diseases

Smooth implementation

Imagine Eyes has supported dozens of clinical investigations that used rtx1 imaging devices. Based on this experience, we offer all the services required for a successful implementation of rtx1 biomarkers in studies and trials of various phases.

Evidence from published studies

Clinical investigations in inherited retinal dystrophy (IRD) and age-related macular degeneration (AMD) have shown that rtx1 detects disease progression in less than 6 months in IRD[1], and less than 1 month in dry AMD[2]. First implementation in therapeutic studies have allowed investigators to confirm the structural stability of transplanted epithelial stem cells in wet AMD[3], and to monitor signs of inflammatory response[4] and photoreceptor cell rescue[5] weeks after gene therapy in IRD.

More about the technology

rtx1 delivers highly sensitive biomarkers thanks to *adaptive optics* (AO) imaging, a technology that enables examining photoreceptor cells, RPE cells and blood vessel structure in patients' retinas.

Contacts

Nicolas Chateau, PhD
Co-founder & Chief Executive Officer

Marine Durand
Product Manager Retinal Imaging

Laurent Vabre, PhD
Manager Sales & Support

[1] Roshandel et al., *TVST*, 2021, DOI: 10.1167/tvst.10.14.11
[2] Gocho et al., *IOVS,* 2013, DOI: 10.1167/iovs.12-10672
[3] Takagi et al., *Ophthalmol Ret,* 2019, DOI: 10.1016/j.oret.2019.04.021
[4] Kortuem et al. *Acta Ophthalmol*, 2023, DOI: 10.1111/aos.15765
[5] Kortuem et al. *Acta Ophthalmol*, 2021, DOI: 10.1111/aos.14990

Imagine Eyes S.A. 18 rue Charles de Gaulle, 91400 Orsay, FRANCE
www.imagine-eyes.com
✉ contact@imagine-eyes.com

rtx1 is certified medical device of class IIa in the European Union. rtx1 is an approved medical device in Japan, China and Korea. In the USA, rtx1 has not received FDA clearance; it is an investigational device that requires Institutional Review Board (IRB) oversight.

© 2024.04 Imagine Eyes S.A all rights reserved.